相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience
Valerie E. Crolley et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer
Daniel A. Goldstein et al.
CANCER MEDICINE (2020)
Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results
Daniel Thomas et al.
CANCER RESEARCH (2020)
Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Pathologic Evaluation and Prognostic Implications of Nodal Micrometastases in Breast Cancer
Sunil W. Dutta et al.
SEMINARS IN RADIATION ONCOLOGY (2019)
The effect of Oncotype DX® on adjuvant chemotherapy treatment decisions in early breast cancer
M. A. Rabie et al.
ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND (2019)
Controversies in locoregional management of breast cancer with low volume pN0(i+) and pN1mi nodal disease
Maryam Dosani et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era
Eleftherios P. Mamounas et al.
NPJ BREAST CANCER (2018)
The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jagar Jasem et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry
Salomon M. Stemmer et al.
NPJ BREAST CANCER (2017)
Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK
J. Loncaster et al.
EJSO (2017)
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
Robert C. Stein et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Breast Cancer 2 Gene expression profiling in breast cancer: classification, prognostication, and prediction
Jorge S. Reis-Filho et al.
LANCET (2011)
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
K. David Voduc et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer
Gordon C. Wishart et al.
BREAST CANCER RESEARCH (2010)
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays
Kathy S. Albain et al.
BREAST (2009)
Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer
Ruth Oratz et al.
JOURNAL OF ONCOLOGY PRACTICE (2007)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
